JAK2 and essential thrombocythemia: In patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF), acquired mutations in genes such as JAK2 tyrosine kinase, calreticulin (CALR), and myeloproliferative leukemia virus (MPL) have been described [1]–[3].